Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment.
AbbVie's Hepatitis C Treatment Shows Promise
Comment
Show comments
Hide Comments
